Alassani Fousséni, Tchangai Boyodi, Bagny Aklesso, Adani-Ife Ablavi A, Amavi Kossigan A, Darre Tchin, Attipou Komla
Department of Visceral Surgery, University Teaching Hospital of Lomé, Lomé, Togo.
Department of Hepato-Gastro-Enterology, University Teaching Hospital of Lomé, Lomé, Togo.
Oncol Ther. 2019 Dec;7(2):159-164. doi: 10.1007/s40487-019-00101-4. Epub 2019 Nov 2.
Although the standard treatment for stromal tumours is surgery, in locally advanced forms, it is often necessary to achieve tumour downstaging to improve surgical outcomes. Neoadjuvant treatment in gastrointestinal stromal tumours (GISTs) with tyrosine kinase inhibitors, including imatinib, has been shown to be effective in several studies, but the duration of this treatment is still a subject of debate.
We report a case of a large GIST of the stomach in a 51-year-old patient with atypical presentation that was initially unresectable. Neoadjuvant treatment with imatinib for 16 months resulted in a good response, allowing secondary surgical excision.
Imatinib in neoadjuvant therapy should be continued as long as there is a good response and tolerance to the medication to obtain tumour downsizing compatible with carcinologic excision.
尽管间质瘤的标准治疗方法是手术，但对于局部晚期病例，通常需要使肿瘤降期以改善手术效果。多项研究表明，使用包括伊马替尼在内的酪氨酸激酶抑制剂对胃肠道间质瘤（GIST）进行新辅助治疗是有效的，但这种治疗的持续时间仍是一个有争议的话题。
我们报告了一例51岁胃巨大GIST患者，其临床表现不典型，最初无法切除。使用伊马替尼进行16个月的新辅助治疗产生了良好的反应，从而得以进行二期手术切除。
只要对药物有良好的反应和耐受性，新辅助治疗中的伊马替尼就应持续使用，以实现与肿瘤学切除相适应的肿瘤缩小。
